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Abstract Previously, we demonstrated that ferulate ethyl and 
tocopherol reduced HIV replication. In this study, we investigate 
whether the conjugation of both compounds (O-tocopheryl 
succinyl O-ethyl ferulate) can increase HIV inhibition. We show 
here for the first time that O-tocopheryl succinyl O-ethyl ferulate 
inhibits 80% of HIV replication (HIV-1 acute infection and HIV 
transmission), inhibits cell lipoperoxidation and prevents cellular 
glutathione consumption. Compared to ferulate ethyl and 
tocopheryl succinyl, O-tocopheryl succinyl O-ethyl ferulate 
inhibits more HIV replication. This may be due in part to the 
great increase in the lipophilicity of this compound. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
H u m a n immunodeficiency virus type 1 (HIV-1) is the pri-
mary etiology of the acquired immunodeficiency syndrome 
(AIDS) [1-3]. In recent reports, cellular antioxidant status 
was suggested to be an important factor determining HIV 
activation [4]. It has been suggested that the shift in the anti-
oxidant balance towards the pro-oxidant side contributes to 
the self-perpetuation of viral replication, immunodysregula-
tion, and AIDS-Kaposi ' s sarcoma pathogenesis [4-8]. 
Already in the early stages of the disease, low plasma levels 
of acid-soluble thiol and reduced GSH are observed, and 
these continue to decline as the disease progresses [4,6]. Defi-
ciencies in antioxidant enzymes (superoxide dismutase (SOD) 
[9], glutathione peroxidase and other antioxidants (ascorbic 
acid, tocopherol, carotenoids and selenium)) are observed in 
HIV-1 infected patients (reviewed in [4,10]). In addition, ele-
vated serum levels of lipid peroxidation products, such as 
hydroperoxides and malondialdehyde (MDA) , have been re-
ported by several authors [4]. 
HIV-1 expression can be induced by oxidants such as hy-
drogen peroxide and singlet oxygen in vitro [11]. At the same 
time, HIV-1 can increase reactive oxygen species (ROS) accu-
mulation via a ^raws-acting transcriptional activator (Tat) [12]. 
Tat acts as a pro-oxidant protein by activating proinfiamma-
tory cytokine secretion ( T N F a , interleukin (IL)-l , IL6, 
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TGF(3) [12] known to increase ROS production [13,14], and 
weakening cellular antioxidant defense mechanisms via sup-
pression of Mn-SOD expression [15,16]. All these findings 
suggest that ROS and HIV infection form an autocatalytic 
vicious circle which finally renders cells more sensitive to the 
cytotoxic effects of T N F a and increases their susceptibility to 
undergo apoptosis [4,5,17-19]. 
Previously, we demonstrated that ferulic acid and tocopher-
ol hemisuccinate reduced HIV replication in the chronically 
HIV-1 infected promonocytic U l cell line [20,21]. In addition, 
we showed that ethyl ferulate, which is more lipophilic than 
ferulic acid, potentiated HIV inhibition [20]. In this study, we 
made a conjugate from the two molecules and investigated 
whether this conjugate, tocopheryl hemisuccinate with ethyl 
ferulate, can increase HIV inhibition. 
2. Materials and methods 
2.1. Chemicals 
Ferulic acid and a-tocopherol acid succinate were purchased from 
Sigma. The structures of O-tocopheryl succinyl O-ethyl ferulate is 
presented in Fig. 1. It was synthesized as described in [22]. The phys-
ico-chemical study of this compound has been described by Barthe-
lemy et al. [22]. 
2.2. Cells and culture conditions 
The p24 antigen (HIV core protein) assay was chosen for this. 
Antigen levels were quantified by enzyme linked immunosorbent 
(ETISA, Du Pont Co., Delaware) in centrifuged culture supernatants 
from three different models of HIV infected cells: 
2.2.1. Ul cell line. The Ul cell line was derived from chronically 
HIV-1 infected promonocytic U937 cells surviving an acute infection 
[23]. The cells were cultivated in a humidified 5% C0 2 environment at 
37°C, in RPMI 1640 (Gibco BRL, New York) supplemented with 
10°/) fetal calf serum, L-glutamine and penicillin-streptomycin (Gibco 
BRL). Ul cells (3X 105 IU cells) were pretreated with or without O-
tocopheryl succinyl O-ethyl ferulate for 1 h. Subsequently, 100 U/ml 
of recombinant TNFa (R&D Systems, Minneapolis, MN) was ap-
plied to each well. After incubation for 24 or 48 h, the culture medium 
was collected and assayed for p24 gag antigen levels. All the experi-
ments were performed in triplicate. Cell survival was determined by 
trypan blue dye exclusion. 
2.2.2. HIV propagation in peripheral blood mononuclear cells 
(PBMCs) activated with PHA and IL2. PBMCs obtained from 
HIV-1 seronegative donors were isolated by Ficoll-Hypaque density 
sedimentation (Pharmacia, Sweden) and incubated at a density of 
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Fig. 1. Structures of O-tocopheryl succinyl O-ethyl ferulate. 
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2X106 cells/ml in RPMI 1640, supplemented with 10% inactivated 
fetal calf serum, 3 mg/ml PHA (Sigma, Paris) and 5% v/v IL-2 (Gib-
co). After 48 h, the cells were washed and cocultivated with an equal 
number of PBMCs obtained from HIV-1 infected patients under the 
same culture conditions at a total cell concentration of 2X 106 cells/ml 
in complete medium and incubated with or without O-tocopheryl 
succinyl O-ethyl ferulate. The supernatants of cocultures were assayed 
for p24 gag antigen in comparison to untreated cocultures after var-
ious cultivation periods (5, 7, 10 and 13 days). 
2.2.3. HIV infection of monocyte-derived macrophages 
(MDM). Monocytes were isolated from healthy PBMCs by coun-
tercurrent centrifuge elutriation (Beckman Instruments, California). 
Monocytes were cultured for 5 days in RPMI 1640 medium supple-
mented with 10% inactivated fetal calf serum, L-glutamine and pen-
icillin-streptomycin. This procedure permits monocyte differentiation 
and produces a maximal sensitivity for productive infection. The pres-
ence of the membrane antigens CD64, CD4, CD11B and MAXI was 
investigated by flow cytometry. After 5 days, 2 X106 cells were washed 
in phosphate buffered saline (PBS) and infected for 3 h with HIV-1 
Ba-L (10 TCID 50/106 cells), kindly provided by Dr. A.M. Aubertin 
(Strasbourg, France). The medium was then removed and replaced 
twice weekly with fresh complete medium. After incubation for 7 
and 14 days the culture medium was collected and assayed for p24 
gag antigen levels. O-Tocopheryl succinyl O-ethyl ferulate was added 
both during the pre-infection period (24 h) and during the post-in-
fection periods. 
2.3. Measurement of lipid peroxidation 
Ul cells (1 X 106 cells) were cultured in complete medium with O-
Tocopheryl succinyl O-ethyl ferulate for 24 h. Subsequently, 100 U/ml 
of recombinant TNFa was added. After 24 h, cells were washed and 
pelleted and lipid peroxidation and GSH were measured. All experi-
ments were performed in triplicate. Lipid peroxidation was evaluated 
by determining the Ul cell content of the thiobarbituric reactive sub-
stances (TBARS), according to the method of Yagi [24]. The relative 
fluorescence intensity of the TBARS was measured in a Kontron 
SFM 25 spectrofluorimeter with excitation and emission wavelengths 
of 515 and 548 nm, respectively. The concentration of lipid peroxides 
was expressed in terms of TBARS (nmol/mg protein), using MDA as 
a standard. 
2.4. Determination of total glutathione 
The total GSH level of Ul cells was determined by a kinetic assay 
involving the continuous reduction of 5,5'-dithiobis-(2-nitrobenzoic 
acid) by NADPH as originally described by Tietze [25]. The gluta-
thione results are expressed in nmol/mg protein. 
TNF+ 1|iM TNF+5nM 
Fig. 2. Effect of O-tocopheryl succinyl O-ethyl ferulate on TNFa in-
duced latency reactivation in Ul cells. Cells were pretreated with 1, 
5 and 10 |xM of O-tocopheryl succinyl O-ethyl ferulate for 1 h and 
then stimulated with TNFa (100 U/ml). After 48 h, the superna-
tants were harvested and antigen p24 was measured. Values are 
mean+S.E., « = 3. *P<0.05. 
2.5. Reduction of DPPH 
The scavenger potency of O-tocopheryl succinyl O-ethyl ferulate, 
ferulate ethyl and tocopherol was determined by the reduction of 1,1-
diphenyl-2-picryl hydrazyl stable free radical. Equal volumes of equi-
molar solutions of DPPH and each test compound dissolved in etha-
nol were mixed. Ethanol was added to the control solution. The 
absorbance at 517 nm was measured after 20 min. The difference in 
absorbance between test compound and control was recorded as the 
reducing activity. Each experiment was performed in triplicate. The 
standard deviation of absorbance values was less than 10%. 
2.6. Statistics 
All results are expressed as mean ± S.E. Comparisons of results 
were done using ANOVA test. P < 0.05 was considered significant. 
3. Results 
3.1. Effect of O-tocopheryl succinyl O-ethyl ferulate on TNFa 
induced latency reactivation in Ul cells 
In order to determine whether O-tocopheryl succinyl O-eth-
yl ferulate can modulate TNFa induced p24 antigen produc-
tion, we pretreated the Ul cells with 1, 5, and 10 uM of 
lipophilic redox conjugate for 1 h before TNFa stimulation. 
Antigen p24 was measured 48 h after TNFa stimulation. In 
the absence of stimulus, Ul cells produced very low amounts 
of p24 antigen [23]. Stimulation with TNFa resulted in the 
induction of p24 antigen in the culture supernatants (Fig. 2). 
Pretreatment for 1 h with O-tocopheryl succinyl O-ethyl fer-
ulate induced a significant reduction of p24 antigen produc-
tion, respectively 22, 41 and 63% 48 h after TNFa exposure 
(Fig. 2). In the absence of TNFa, O-tocopheryl succinyl O-
ethyl ferulate had no effect on the viability of Ul cells (as 
determined by trypan blue dye exclusion) or on p24 antigen 
production (data not shown). 
3.2. Effect of O-tocopheryl succinyl O-ethyl ferulate on HIV-1 
propagation in PBMCs activated with PHA and IL2 
PBMCs obtained from HIV-1 infected patients were incu-
bated with PHA blasts prepared from HIV-1 seronegative 
controls in the presence or absence of O-tocopheryl succinyl 
O-ethyl ferulate. This compound was added at the start and at 
all time points of cell culture. Supernatants were harvested at 
days 7 and 14 and p24 antigen was quantified. In control 
coculture, we observed a progressive increase in supernatant 
p24 antigen expression (Table 1). 1 uM of O-tocopheryl suc-
cinyl O-ethyl ferulate decreased p24 antigen expression (33% 
at day 14). This inhibitory effect increased with 5 uM of O-
Table 1 
Effects of O-tocopheryl succinyl O-ethyl ferulate on HIV-1 propaga-
tion in PBMCs activated with PHA and IL-2 
Compound Days of culture 
14 
0 
1 uM 
5 uM 
10 uM 
150± 13 
100 ±5* 
90 ±7* 
85 ± 10* 
15000 ±850 
10000 ±900* 
7500 ±400* 
3080 ±700* 
PBMCs obtained from HIV-1 infected patients were incubated with 
PBMCs activated with PHA and IL-2 from HIV-1 seronegative con-
trols in the presence of 0, 1, 5 and 10 uM of O-tocopheryl succinyl O-
ethyl ferulate. This compound was added at the start and at all time 
points of cell culture. Supernatants were harvested at days 7 and 14 
and p24 antigen was quantified. Data shown are mean ± S.E. of trip-
licate wells of p24 antigen (pg/ml), n = 3; *P<0.05. 
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Fig. 3. Effects of O-tocopheryl succinyl O-ethyl ferulate in acute 
HIV infection of MDM. 1, 5 and 10 uM of O-tocopheryl succinyl 
O-ethyl ferulate was added to medium 24 h before HIV infection 
(pre-infection period), at the time of HIV infection (day 0) and at 
days 3 and 7 (post-infection period). Supernatants were harvested 
and antigen p24 was measured at days 0, 7 and 14. Values are 
mean+S.E., n = 3. 
tocopheryl succinyl O-ethyl ferulate (50% at day 14), and at 
10 uM we obtained 80% of HIV inhibition. O-Tocopheryl 
succinyl O-ethyl ferulate at all concentrations used in these 
studies had no effect on viability of PBMCs, as determined 
by trypan blue dye exclusion (data not shown). 
3.3. Effect of exogenous O-tocopheryl succinyl O-ethyl ferulate 
on HIV-1 infected macrophages 
We studied the effects of O-tocopheryl succinyl O-ethyl fer-
ulate in a model of acute HIV infection of primary differen-
tiated monocytes. This compound was added to medium 24 h 
before HIV infection (pre-infection period), at the time of 
HIV infection (day 0) and at days 3 and 7 (post-infection 
period). O-Tocopheryl succinyl O-ethyl ferulate at 1, 5 and 
10 uM significantly reduced p24 antigen production respec-
tively by 36, 45 and 52% at 7 days post-infection and by 40, 
60 and 80%o at 14 days post-infection (Fig. 3). No cytopathic 
effects were observed with O-tocopheryl succinyl O-ethyl fer-
ulate treatment, using phase contrast microscopy. 
3.4. Effect of O-tocopheryl succinyl O-ethyl ferulate on TNFa 
induced oxidative stress 
Several lines of evidence implicate free radicals as a medi-
ator of TNF induced cell injury characterized by a reduction 
in cellular GSH and increased accumulation of lipoperoxida-
tion products [4,5]. In order to determine whether O-toco-
pheryl succinyl O-ethyl ferulate could protect Ul cells against 
TNFa ROS cytotoxic effects, we measured intracellular GSH 
and MDA production. TNFa induced a 56% decrease in cel-
lular GSH content compared to control cells (45 ± 3 nmol/106 
cells). In cells preloaded with O-tocopheryl succinyl O-ethyl 
ferulate (10 (J.M), TNFa did not induce a decrease in the cells' 
GSH. 
Concerning lipid peroxide concentration, a 120%> increase in 
cellular TBARS was observed in TNFa treated cells com-
pared to control cells (2.0 ±0.5 nmol/mg protein). O-Toco-
pheryl succinyl O-ethyl ferulate induced a marked decrease 
in TNFa induced TBARS production ( P < 0.004). Culture 
supernatants did not contain any detectable amount of these 
lipoperoxidation products (data not shown). 
3.5. Reducing activity against DPPH free radical 
In order to determine the antioxidant activity of the con-
jugate and the two precursor molecules, we studied their re-
ducing activities towards DPPH free radical. The percentage 
scavenging effect was calculated from the control where no 
compound was present. Ferulate exhibited higher scavenging 
activity, i.e. 64%>. O-Tocopheryl succinyl O-ethyl ferulate and 
tocopherol hemisuccinate were completely 'inactive' because 
their chemical properties were modified during synthesis by 
blocking the phenolic groups. 
4. Discussion 
In the present study we show that pretreatment with the 
lipophilic redox conjugate O-tocopheryl succinyl O-ethyl fer-
ulate significantly inhibited cell lipoperoxidation, prevented 
cellular GSH consumption and decreased HIV replication 
up to 80%. 
Our results demonstrate that O-tocopheryl succinyl O-ethyl 
ferulate has an inhibitory effect on both HIV latency and 
development of HIV infection. To determine the effects of 
O-tocopheryl succinyl O-ethyl ferulate in a model system of 
viral latency, we used the Ul cell line, because it is a 'non-
expressing cell', characterized by a state of relative latency and 
lack of detectable virion production [23]. HIV-1 expression 
can be induced in these cells by a variety of stimuli including 
inflammatory cytokines, oxidants [4] and clastogenic factors 
[19]. In this study, we used TNFa to activate HIV expression, 
because many of the symptoms associated with AIDS have 
been suggested to be TNFa-mediated [4-6,26]. TNFa is pro-
duced by macrophages and monocytes in response to mild 
oxidant stress and is found in excess in HIV/AIDS patients 
[4] which in turn is known to generate free radicals by a 
variety of cells [26]. TNFa can provide an 'amplification 
loop' which feeds back to further excite production of ROS 
from macrophages and neutrophils [4]. 
The effects of our lipophilic redox conjugate on acute HIV-
1 infection were investigated in MDM infected with HIV-1 
Ba-L. The reasons we selected the MDM and the macropha-
gotropic strain HIV-1 Ba-L in this model of HIV infection are 
that monocytes play a central role in the pathogenesis of HIV 
infection. The chronically infected monocyte serves as a con-
stant reservoir of the virus [1]. Transmission of HIV-1 infec-
tion from one individual to another appears to be primarily 
due to monocytotropic strains that do not induce syncytia 
[27]. O-Tocopheryl succinyl O-ethyl ferulate inhibits HIV ex-
pression by 80%o, indicating that in our experimental condi-
tions, the lipophilic redox conjugate can interact at several 
steps of HIV expression. 
To investigate the effect of O-tocopheryl succinyl O-ethyl 
ferulate in HIV transmission from HIV infected to uninfected 
PBMCs, we used PBMC coculture activated with PHA and 
IL2. O-Tocopheryl succinyl O-ethyl ferulate markedly de-
creased HIV expression and propagation in PBMC coculture. 
These findings strongly suggest the major involvement of ox-
idative stress in HIV expression. We can explain these results 
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by the findings of Kimura et al. who demonstrated the am-
plification of free radical production in cells of mononuclear 
phagocytes by HIV infection [28]. It was also shown that free 
radicals were able to enhance cell-to-cell transmission of HIV 
in a cultured human CD4 cell line [29]. 
We show here that when cells were preincubated with O-
tocopheryl succinyl O-ethyl ferulate for 24 h, TNF induced 
MDA production was markedly inhibited and GSH decrease 
was prevented. Thus, we suggest that O-tocopheryl succinyl 
O-ethyl ferulate may increase the cell's ability to reduce the 
activation of the nuclear factor kappa-B ( N F - K B ) and inhibit 
HIV replication. 
Previously, we demonstrated that superoxide anion is im-
plicated in chronic infection (Ul cell line), acute infection 
(HIV infected MDM) and in HIV propagation in PBMC 
coculture [17-19]. We also demonstrated that ferulic acid 
and its ester can inhibit HIV replication; this inhibition was 
more pronounced with ferulate ethyl than ferulic acid [20], 
which is more lipophilic as demonstrated by Barthelemy et 
al. [22]. In this study we show that conjugation of tocopherol 
acid succinate with ferulic acid ethyl significantly inhibits HIV 
replication in three different models of HIV infected cells. 
Compared to our previous studies [20,21], the HIV inhibition 
obtained with O-tocopheryl succinyl O-ethyl ferulate was 
higher (80%) than with ferulate ethyl and tocopherol. This 
may be explained by the fact that this conjugate has a higher 
lipophilicity score (than tocopheryl succinyl and ethyl feru-
late) enabling a better incorporation into the lipidic part of 
the cell membrane and the exertion of its antioxidant effect at 
the true site of lipoperoxidation. This hypothesis is probable, 
because the conjugation of both compounds increases their 
lipophilicity scores [22]. In vitro, we found that O-tocopheryl 
succinyl O-ethyl ferulate was completely inactive towards 
DPPH free radical, because during chemical synthesis, all phe-
nolic groups (OH) were blocked. However, further studies are 
being undertaken in our laboratory to investigate the antiox-
idant activity in vitro and whether this conjugate stays intact 
or can be separated into two moieties: tocopheryl hemisucci-
nate (remains in cell membrane) and ferulic acid (penetrates 
the cell). 
Despite uncertainty about the specific intracellular mecha-
nisms inhibited by O-tocopheryl succinyl O-ethyl ferulate, it 
remains from these ex vivo experiments that O-tocopheryl 
succinyl O-ethyl ferulate represents a non-toxic molecule 
with a high potentiality for therapeutic involvement against 
HIV-1 infection. 
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